Globus Medical price target lowered to $93 from $95 at Wells Fargo

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the shares. The firm says Globus Medical put up a solid Q4 print that was in line with the January 8 pre-announcement. Nevro (NVRO) deal close expected in late Q2 and Wells gets the sense investors are confident in Globus’ ability to successfully integrate Nevro following the NuVasive integration.